Characteristics of Commonly Prescribed Nonsteroidal Antiinflammatory Drugs
| Dose | Pharmacokinetics | Generic Name (Trade Name) | Available Dosages (mg) | Common Dosing Intervals | Drug Metabolism | Elimination Half-Life (h) | Nonselective NSAIDs Acetic Acid Group | | | | | Diclofenac DR | 25 | BID-TID | Oxidation | 1-2 | (Voltaren) | 50 | QD-BID | | | Diclofenac XR | 75 | | | | (Voltaren XR) | 100 | | | | Etodolac | 200 | BID-TID | Oxidation, conjugation | 7 | (Lodine) | 300 | QD | | | Etodolac XL | 400 | | | | (Lodine XL) | 500 | | | | | 400 | | | | | 500 | | | | | 600 | | | | Ketorolac IM, IV injection | 30 | QD-QID | Conjugation | 2.5-8.5 | (generic) | | | | | Indomethacin | 25 | BID-TID | Oxidation, conjugation | 4.5-6 | (Indocin) | 50 | QD-BID | | | Indomethacin SR | 75 | | | | (Indocin SR) | | | | | Nabumetone | 500 | QD-BID | Oxidation | 22-30 | (Relafen) | 750 | | | | Sulindac | 150 | BID | Oxidation, reduction | 16 | (Clinoril) | 200 | | | | Tolmetin | 400 | TID | Conjugation | 5 | (Tolectin) | 600 | | | | Oxicam Group | | | | | Meloxicam | 7.5 | QD | Oxidation | 13-20 | (Mobic) | 15 | | | | Piroxicam | 10 | QD | Oxidation | 30-86 | (Feldene) | 20 | | | | Propionic Acid Group | | | | | Fenoprofen | 200 | TID-QID | Glucuronidation | 3 | (Nalfon) | 300 | | | | Flurbiprofen | 50 | BID-QID | Oxidation | 3-6 | (Ocufen) | 100 | | | | Ibuprofen | 400 | TID-QID | Oxidation | 2-2.5 | (Motrin) | 600 | | | | | 800 | | | | Ketoprofen | 50 | TID-QID | Conjugation | 2-4 | | 75 | QD | | 3-7 | Ketoprofen CR | 100 | | | | | 150 | | | | | 200 | | | | Naproxen | 250 | BID | Conjugation, oxidation | 12-15 | (Naprosyn) | 375 | QD | | | (Naprelan) | 500 | | | | | 375 | | | | | 500 | | | | Oxaprozin (Daypro) | 600 | QD-BID | Oxidation, conjugation | 50-60 | Salicylate | | | | | Aspirin | 81 | QD | Hydrolysis, conjugation, glucuronidation | 0.25-0.5 | (Ecotrin, Ascriptin) | 325 | BID-QID | | Choline magnesium | 500 | BID-TID | | | | 500 | | | | Trisalicylate | 750 | | Conjugation | 2-12 | (Trilisate) | 1000 | | | | Cyclooxygenase-2 Agents Coxib Group | | | | | Celecoxib | 100 | QD-BID | Conjugation | 11-16 | (Celebrex) | 200 | | | |
|
aA dosage range exists for each NSAID that must be individualized depending on patient characteristics and disease mechanism.
Reproduced from Vincent JL, Abraham E, Moore FA, et al. Textbook of Critical Care, 6th ed. Philadelphia, PA: Elsevier Saunders; 2011:1346-1353.